Protease inhibitor use in 233 pregnancies

Anne B. Morris, Ana Rua Dobles, Susan Cu-Uvin, Carmen Zorrilla, Jean Anderson, Joseph I. Harwell, Jean M Keller, Jane Garb

Research output: Contribution to journalArticle

Abstract

Background: In the United States, as most highly active antiretroviral therapy (HAART) regimens used during pregnancy in HIV-infected women include a protease inhibitor (PI), it is important to determine the effects of PIs specifically rather than all HAART regimens. Prospective trials employing HAART during pregnancy are ongoing. Objective: To better understand the effects of PI use during pregnancy on prematurity, maternal and infant adverse events, and infant outcomes. Results: A total of 233 pregnancies in which PIs were used were reported, including 5 sets of twins and 1 set of triplets. Perinatal transmission is documented in 2 of 221 infants for a rate of 0.9% (95% CI, 0%-2.2%). Both HIV-positive infants were delivered by cesarean section (one elective at 37 1/7 weeks and one unscheduled at 32 6/7 weeks). The prematurity rate (

Original languageEnglish (US)
Pages (from-to)30-33
Number of pages4
JournalJournal of Acquired Immune Deficiency Syndromes
Volume40
Issue number1
DOIs
StatePublished - Sep 1 2005

Fingerprint

Protease Inhibitors
Highly Active Antiretroviral Therapy
Pregnancy
HIV
Cesarean Section
Mothers

Keywords

  • Perinatal transmission
  • Pregnancy
  • Protease inhibitors

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Morris, A. B., Dobles, A. R., Cu-Uvin, S., Zorrilla, C., Anderson, J., Harwell, J. I., ... Garb, J. (2005). Protease inhibitor use in 233 pregnancies. Journal of Acquired Immune Deficiency Syndromes, 40(1), 30-33. https://doi.org/10.1097/01.qai.0000174651.40782.95

Protease inhibitor use in 233 pregnancies. / Morris, Anne B.; Dobles, Ana Rua; Cu-Uvin, Susan; Zorrilla, Carmen; Anderson, Jean; Harwell, Joseph I.; Keller, Jean M; Garb, Jane.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 40, No. 1, 01.09.2005, p. 30-33.

Research output: Contribution to journalArticle

Morris, AB, Dobles, AR, Cu-Uvin, S, Zorrilla, C, Anderson, J, Harwell, JI, Keller, JM & Garb, J 2005, 'Protease inhibitor use in 233 pregnancies', Journal of Acquired Immune Deficiency Syndromes, vol. 40, no. 1, pp. 30-33. https://doi.org/10.1097/01.qai.0000174651.40782.95
Morris, Anne B. ; Dobles, Ana Rua ; Cu-Uvin, Susan ; Zorrilla, Carmen ; Anderson, Jean ; Harwell, Joseph I. ; Keller, Jean M ; Garb, Jane. / Protease inhibitor use in 233 pregnancies. In: Journal of Acquired Immune Deficiency Syndromes. 2005 ; Vol. 40, No. 1. pp. 30-33.
@article{c5c8cfc8c8434e8eb8d94cfc74f62cb6,
title = "Protease inhibitor use in 233 pregnancies",
abstract = "Background: In the United States, as most highly active antiretroviral therapy (HAART) regimens used during pregnancy in HIV-infected women include a protease inhibitor (PI), it is important to determine the effects of PIs specifically rather than all HAART regimens. Prospective trials employing HAART during pregnancy are ongoing. Objective: To better understand the effects of PI use during pregnancy on prematurity, maternal and infant adverse events, and infant outcomes. Results: A total of 233 pregnancies in which PIs were used were reported, including 5 sets of twins and 1 set of triplets. Perinatal transmission is documented in 2 of 221 infants for a rate of 0.9{\%} (95{\%} CI, 0{\%}-2.2{\%}). Both HIV-positive infants were delivered by cesarean section (one elective at 37 1/7 weeks and one unscheduled at 32 6/7 weeks). The prematurity rate (",
keywords = "Perinatal transmission, Pregnancy, Protease inhibitors",
author = "Morris, {Anne B.} and Dobles, {Ana Rua} and Susan Cu-Uvin and Carmen Zorrilla and Jean Anderson and Harwell, {Joseph I.} and Keller, {Jean M} and Jane Garb",
year = "2005",
month = "9",
day = "1",
doi = "10.1097/01.qai.0000174651.40782.95",
language = "English (US)",
volume = "40",
pages = "30--33",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Protease inhibitor use in 233 pregnancies

AU - Morris, Anne B.

AU - Dobles, Ana Rua

AU - Cu-Uvin, Susan

AU - Zorrilla, Carmen

AU - Anderson, Jean

AU - Harwell, Joseph I.

AU - Keller, Jean M

AU - Garb, Jane

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Background: In the United States, as most highly active antiretroviral therapy (HAART) regimens used during pregnancy in HIV-infected women include a protease inhibitor (PI), it is important to determine the effects of PIs specifically rather than all HAART regimens. Prospective trials employing HAART during pregnancy are ongoing. Objective: To better understand the effects of PI use during pregnancy on prematurity, maternal and infant adverse events, and infant outcomes. Results: A total of 233 pregnancies in which PIs were used were reported, including 5 sets of twins and 1 set of triplets. Perinatal transmission is documented in 2 of 221 infants for a rate of 0.9% (95% CI, 0%-2.2%). Both HIV-positive infants were delivered by cesarean section (one elective at 37 1/7 weeks and one unscheduled at 32 6/7 weeks). The prematurity rate (

AB - Background: In the United States, as most highly active antiretroviral therapy (HAART) regimens used during pregnancy in HIV-infected women include a protease inhibitor (PI), it is important to determine the effects of PIs specifically rather than all HAART regimens. Prospective trials employing HAART during pregnancy are ongoing. Objective: To better understand the effects of PI use during pregnancy on prematurity, maternal and infant adverse events, and infant outcomes. Results: A total of 233 pregnancies in which PIs were used were reported, including 5 sets of twins and 1 set of triplets. Perinatal transmission is documented in 2 of 221 infants for a rate of 0.9% (95% CI, 0%-2.2%). Both HIV-positive infants were delivered by cesarean section (one elective at 37 1/7 weeks and one unscheduled at 32 6/7 weeks). The prematurity rate (

KW - Perinatal transmission

KW - Pregnancy

KW - Protease inhibitors

UR - http://www.scopus.com/inward/record.url?scp=24144457513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144457513&partnerID=8YFLogxK

U2 - 10.1097/01.qai.0000174651.40782.95

DO - 10.1097/01.qai.0000174651.40782.95

M3 - Article

C2 - 16123678

AN - SCOPUS:24144457513

VL - 40

SP - 30

EP - 33

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -